WALTHAM, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC:ABOS) (BULLETIN BOARD: ABOS) , a company developing proprietary medical devices and cell-based therapies for the millions of patients each year who experience or are at risk for life-threatening episodes of liver failure, today announced that Walter C. Ogier, President and Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 8th Annual Healthcare Conference at The Palace Hotel in New York City. As part of his presentation, Mr. Ogier will review the recently reported data from the first five patients treated with the SEPET(TM) Liver Assist Device in the Company's ongoing feasibility IDE clinical trial as well as preliminary results of treatment of additional patients in the clinical trial. Mr. Ogier is scheduled to speak on Wednesday, November 8, 2006 at 11:20AM Eastern Time in the Holmes I room. The Company's presentation at the conference will be available via web cast by accessing http://www.wsw.com/webcast/rrshq10/abos, or through the Arbios website at http://www.arbios.com/. About Arbios Systems Arbios Systems, Inc. is developing proprietary medical devices and cell- based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET(TM) Liver Assist Device, a novel blood purification therapy that provides enhanced "liver dialysis," and the HepatAssist(TM) Cell-Based Liver Support System, a bioartificial liver that combines blood detoxification with liver cell therapy to replace whole liver function in patients with the most severe forms of liver failure. For more information on the Company, please visit http://www.arbios.com/. This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to future markets for the Company's products and goals and objectives of the Company's product and clinical development programs.. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the Company. Arbios cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. Please refer to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005 for a description of risks that may affect our results or business conditions. The Company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events except as required by law. SEPET(TM) and HepatAssist(TM) are trademarks of Arbios Systems, Inc. DATASOURCE: Arbios Systems, Inc. CONTACT: Contact at Arbios: Walter C. Ogier, +1-781-839-7293, ; or Contact at Rx Communications Group: Paula Schwartz, Investors, +1-917-322-2216, or Pat Garrison, Media, +1-917-322-2567; or at MacDougall Biomedical Communications: Doug MacDougall, +1-508-647-0209 Web site: http://www.arbios.com/ http://www.wsw.com/webcast/rrshq10/abos

Copyright